Piil Karin, Whisenant Meagan, Mendoza Tito, Armstrong Terri, Cleeland Charles, Nordentoft Sara, Williams Loretta A, Jarden Mary
Department of Oncology, Center for Cancer and Organ Diseases, Copenhagen University Hospital; Rigshospitalet, Copenhagen, Denmark.
University Hospitals Center for Health Research (UCSF) and Center for Integrated Rehabilitation of Cancer Patients (CIRE), Copenhagen, Denmark.
Neurooncol Pract. 2020 Oct 19;8(2):137-147. doi: 10.1093/nop/npaa068. eCollection 2021 Apr.
The complexity of disease- and treatment-related symptoms causes profound distress and deterioration of health-related quality of life among patients with brain tumors. Currently, there is no Danish validated disease-specific instrument that focuses solely on measures of both neurologic and cancer-related symptoms of patients with brain tumors. The MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) is a validated patient self-report questionnaire that measures symptom prevalence, intensity, and interference with daily life. The aim of the present study was to determine the psychometric validity of the Danish translation of the MDASI-BT, and to test its utility in 3 cohorts of Danish patients across the spectrum of the brain cancer disease and treatment trajectory.
A linguistic validation process was conducted. Danish patients with malignant primary brain tumors were included to establish the psychometric validity and reliability of the Danish MDASI-BT. Cognitive debriefing interviews were conducted to support the psychometric properties.
A total of 120 patients participated in this study. Coefficient αs for the symptom and interference subscales indicate a high level of reliability across all items. Corresponding symptom and interference or functional items and subscales in the MDASI-BT and European Organisation for Research and Treatment of Cancer Brain Tumor Module BN20 were significantly correlated. Cognitive debriefing provided evidence for content validity and questionnaire utility as participants were comfortable answering the questions and had no problem with the understandability or number of questions asked.
The MDASI-BT is a simple, concise symptom assessment tool useful for assessing the symptom severity and interference of Danish-speaking patients with brain cancer.
与疾病和治疗相关的症状复杂性会给脑肿瘤患者带来极大痛苦，并导致其健康相关生活质量下降。目前，丹麦尚无经过验证的疾病特异性工具专门用于测量脑肿瘤患者的神经学和癌症相关症状。MD安德森症状问卷脑肿瘤模块（MDASI-BT）是一种经过验证的患者自我报告问卷，用于测量症状的发生率、强度以及对日常生活的干扰。本研究的目的是确定MDASI-BT丹麦语翻译版的心理测量效度，并在三组不同脑癌疾病及治疗阶段的丹麦患者中测试其效用。
进行了语言验证过程。纳入丹麦原发性恶性脑肿瘤患者以确定丹麦语MDASI-BT的心理测量效度和信度。进行了认知反馈访谈以支持心理测量特性。
共有120名患者参与了本研究。症状和干扰子量表的α系数表明所有项目的信度都很高。MDASI-BT与欧洲癌症研究与治疗组织脑肿瘤模块BN20中相应的症状、干扰或功能项目及子量表显著相关。认知反馈为内容效度和问卷效用提供了证据，因为参与者回答问题时感到轻松，对问题的可理解性或问题数量没有问题。
MDASI-BT是一种简单、简洁有用的症状评估工具，可用于评估丹麦语脑癌患者的症状严重程度和干扰情况。
